- Conditions
- Obstructive Sleep Apnea, Hypertonia, Muscle, Nasal Airway Obstruction, Tolerance, Trisomy 21, Down Syndrome
- Interventions
- Self-Supporting Nasopharyngeal Airway (ssNPA)
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 8,007
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Immune Deficiency Disorders (PIDD)
- Interventions
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
- Biological
- Lead sponsor
- ADMA Biologics, Inc.
- Industry
- Eligibility
- 6 Years to 75 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- aldesleukin, recombinant interferon alfa, sargramostim
- Biological
- Lead sponsor
- Cancer Treatment Centers of America
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Zion, Illinois
- Conditions
- Communication Disorder, Healthy, Stuttering, Tourette Syndrome, Voice Disorder
- Interventions
- Not listed
- Lead sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,163 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1992 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
- Interventions
- Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Friedreich Ataxia
- Interventions
- CTI-1601
- Drug
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
- Interventions
- Not listed
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- San Francisco, California • Jacksonville, Florida • Ann Arbor, Michigan + 2 more
- Conditions
- Neuronal Ceroid Lipofuscinosis Type 2
- Interventions
- Cerliponase Alfa
- Drug
- Lead sponsor
- David L Rogers, MD
- Other
- Eligibility
- 24 Months to 72 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
- Interventions
- Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem cell infusion
- Drug · Radiation · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Fuchs Dystrophy, Cataract
- Interventions
- BSS Plus, BSS
- Drug
- Lead sponsor
- Adam Fedyk, MD, FACS
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Town and Country, Missouri
- Conditions
- Genetic Disease, Pediatrics, Predictive Model, Clinical Decision Support
- Interventions
- SIGHT Prompted Provider Message
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Intercritical Gout
- Interventions
- Placebo, Rilonacept 80 mg, Rilonacept 160 mg
- Other · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more
- Conditions
- Healthy, Sickle Cell Anemia
- Interventions
- Placebo, PF-07209326
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
- Conditions
- Coronary Artery Disease, Proteus Syndrome, Coffin - Sins Syndrome, Familial Isolated Hyperparathyroidism, Dubouitz Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epidermolysis Bullosa
- Interventions
- Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cystic Fibrosis
- Interventions
- Essential amino acid intake + Leucine vs total AA supplement
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Sickle Cell Disease, Thalassemia
- Interventions
- CordIn
- Biological
- Lead sponsor
- Gamida Cell ltd
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Oakland, California • Washington D.C., District of Columbia
- Conditions
- Subjective Cognitive Complaints, Ehlers-Danlos Syndrome, Cognitive Dysfunction
- Interventions
- COG+OT Telerehabilitation
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina
- Conditions
- Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
- Conditions
- Neurofibromatosis 2, Meningioma
- Interventions
- AZD2014
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Questionnaires/Interviews
- Behavioral
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 10 Years to 13 Years · Female only
- Enrollment
- 188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Haematologic Neoplasms
- Interventions
- AZD2962
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
- Conditions
- Hyperoxaluria, Primary
- Interventions
- Oxabact OC5 - Oxalobacter formigenes Strain HC-1
- Biological
- Lead sponsor
- OxThera
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more